Cancer Targeted Therapy
Cancer targeted therapy is the foundation of precision medicine; it uses drugs or other substances to target specific genes and proteins that control cancer cells’ growth, division and spreading. Compared to traditional chemotherapy drugs, targeted-drugs can specifically act on cancer cells with high efficacy without damaging normal cells. Drugs used in cancer targeted therapy mainly includes small molecules and macromolecules (e.g., monoclonal antibodies), which can target cancer cells and constituents in the tumor microenvironment to activate the immune system. Anti-angiogenesis drugs, such as those targeting vascular endothelial growth factor (VEGF), epidermal growth factor receptor (EGFR), transforming growth factor (TGF)-α, TGF-β, Tumor necrosis factor (TNF)-α, and platelet-derived endothelial growth factor (PDGFR) inhibit the proliferation and metastasis of cancer cells. In recent years, the proportion of antibody drugs in cancer treatment has gradually become prominent. Antibody-drug conjugates (ADCs) are a new type of targeted drugs that are composed of monoclonal antibody, cytotoxic drug and linker. ADCs can deliver drugs to tumor cells and minimize the toxicity to normal tissues. Proteolysis-targeting chimera (PROTAC) is a useful technology for targeted protein degradation. PROTAC exploits the ubiquitin-proteasome system and forms a ternary complex with a hijacked E3 ubiquitin ligase and target protein, leading to polyubiquitination and degradation of the target protein.
Targeted therapy is a useful strategy in treatment of cancer either alone or in combination with standard chemotherapy. At present, targeted therapy has proved significant clinical success in the treatment of many types of cancer, including breast cancer, colorectal cancer, leukemia, ovarian cancer and lung cancer.
-
N-[S-Trityl-L-cysteinyl]glycine
![N-[S-Trityl-L-cysteinyl]glycine](https://file.medchemexpress.com/product_pic/hy-w108635.gif "Click to View N-[S-Trityl-L-cysteinyl]glycine Product Detail")
0 ImagesCat. No.: HY-W108635CAS No.: 26988-61-4N-[S-Trityl-L-cysteinyl]glycine is a cleavable ADC linker.
-
CRBN ligand-703
0 ImagesCat. No.: HY-W952714CAS No.: 2925070-80-8
-
PI-828 (Standard)
0 ImagesCat. No.: HY-108606RCAS No.: 942289-87-4
-
Diethyl heptanedioate
0 ImagesCat. No.: HY-W014126CAS No.: 2050-20-6
-
CRBN ligand-623
0 ImagesCat. No.: HY-W953636CAS No.: 2925100-38-3
-
Ibrutinib Racemate (Standard)
0 ImagesCat. No.: HY-10997ARCAS No.: 936563-87-0Synonyms: PCI-32765 Racemate (Standard)Ibrutinib (Racemate) (Standard) is the analytical standard of Ibrutinib (Racemate). This product is intended for research and analytical applications. Ibrutinib Racemate (PCI-32765 Racemate) is the racemate of Ibrutinib. Ibrutinib is a selective, irreversible Btk inhibitor with IC50 value of 0.5 nM.
-
HKI-357 dimaleate
0 ImagesCat. No.: HY-103443ACAS No.: 915942-25-5
-
Anamorelin (Standard)
0 ImagesSynonyms: RC-1291 (Standard); ONO-7643 (Standard)Anamorelin (Standard) (RC-1291 (Standard)) is the analytical standard of Anamorelin (HY-14734). This product is intended for research and analytical applications. Anamorelin (RC-1291) is an orally active Ghrelin receptor agonist with an EC50 of 0.74 nM. Anamorelin can promote appetite, increase body weight, and stimulate the secretion of growth hormone and insulin-like growth factor-1. Anamorelin can be used in the research of anorexia and cancer cachexia.
-
PD-L1/HDAC-IN-1
0 ImagesCat. No.: HY-172167CAS No.: 2923313-69-1PD-L1/HDAC-IN-1 (Compound 14) is the inhibitor for PD-L1 and HDAC that inhibits PD-1/PD-L1 interaction, HDAC2 and HDAC3 with IC50 of 88.10, 27.98 and 14.47 nM, respectively. PD-L1/HDAC-IN-1 exhibits slight cytotoxicity in MCF-7 (IC50=19.34 μM). PD-L1/HDAC-IN-1 upregulates the expression of PD-L1 and CXCL10, promoting anti-tumour immune response by recruiting T-cell infiltration into TME.
-
Donepezil-d7
0 ImagesCat. No.: HY-W727525CAS No.: 1215071-00-3Synonyms: E2020-d7 free base
-
Salvigenin (Standard)
0 ImagesCat. No.: HY-N1318RCAS No.: 19103-54-9Synonyms: Psathyrotin (Standard)Salvigenin is a natural polyphenolic compound, with neuroprotective effect. Salvigenin has antitumor cytotoxic and immunomodulatory properties. Salvigenin inhibits H2O2-induced cell apoptosis.
-
Nitrobenzylthioinosine 5'-monophosphate
0 ImagesCat. No.: HY-177059CAS No.: 65199-10-2Synonyms: NBMPR-PNitrobenzylthioinosine 5'-monophosphate (NBMPR-P), a nucleoside analog, is a prodrug of the potent nucleoside transport inhibitor Nitro-benzylthioinosine (NBMPR) (HY-W010936). Nitrobenzylthioinosine 5'-monophosphate blocks nucleoside transport in vivo and prevents host toxicity in tumor-bearing mice administered with highdoses of Tubercidin (HY-100126).
-
SC79 (Standard)
0 ImagesCat. No.: HY-18749RCAS No.: 305834-79-1SC79 (Standard) is the analytical standard of SC79 (HY-18749). This product is intended for research and analytical applications. SC79, a unique specific and BBB permeable Akt activator, activates Akt in the cytosol and inhibits Akt membrane translocation. SC79 specifically binds to the PH domain of Akt.
-
tert-Butyl 4-(3-bromopropyl)piperazine-1-carboxylate oxalate
0 ImagesCat. No.: HY-W109687CAS No.: 2102410-31-9
-
CRBN ligand-391
0 ImagesCat. No.: HY-W952750CAS No.: 2925069-56-1
-
MTX-211 (Standard)
0 ImagesCat. No.: HY-107364RCAS No.: 1952236-05-3Synonyms: Mol 211 (Standard)MTX-211 (Standard) (Mol 211 (Standard)) is the analytical standard of MTX-211 (HY-107364). This product is intended for research and analytical applications. MTX-211 (Mol 211) is a dual inhibitor of EGFR and PI3K with IC50 values of ＜100 nM. MTX-211 can be used for the research of cancer and other diseases.
-
FPTI
0 ImagesCat. No.: HY-183395CAS No.: 173374-58-8FPTI is a SYT-SSX1 fusion protein modulator with selective cytotoxicity in SYT-SSX1-positive synovial sarcoma cells. FPTI down-regulates SYT-SSX1 expression and modulates its downstream target genes. FPTI induces apoptosis in synovial sarcoma cells. FPTI can be used for the research of synovial sarcoma.
-
Trifluridine (Standard)
0 ImagesSynonyms: Trifluorothymidine (Standard); 5-Trifluorothymidine (Standard); TFT (Standard)Trifluridine (Standard) is the analytical standard of Trifluridine. This product is intended for research and analytical applications. Trifluridine (Trifluorothymidine) is an irreversible and orally active thymidylate synthase inhibitor, and thereby suppressing DNA synthesis. Trifluridine is an antiviral molecule used for research of HSV, rhabdovirus and orthopoxvirus infection. Trifluridine induces cell apoptosis and autophagy. Trifluridine is also an anticancer agent used in studies of metastatic colorectal cancer, gastrointestinal tumors.
